Introduction {#s1}
============

Influenza A viruses (IAV) infect a wide range of host species but originate from wild birds. Zoonotic transmission from the avian reservoir is initially restricted by host specific species barriers. Infection of new host species requires the virus to bind to cell surface receptors, utilise foreign host cellular proteins whilst evading host restriction factors in order to replicate its genome, and finally transmit between individuals of the new host.

The negative sense RNA genome of influenza A virus (IAV) is replicated in the cell nucleus using a virally encoded RNA-dependent RNA polymerase, a heterotrimer composed of the polymerase basic 1 (PB1), polymerase basic 2 (PB2) and polymerase acidic (PA) proteins together with nucleoprotein (NP) that surrounds the viral RNA, forming the viral ribonucleoprotein complex (vRNP) ([@bib34]).

Crucially, the viral polymerase must co-opt host factors to carry out transcription and replication ([@bib34]). The PB2 subunit is a major determinant of the host restriction of the viral polymerase ([@bib1]). Avian IAV polymerases typically contain a glutamic acid at position 627 of PB2, and mutation to a lysine, the typical residue at this position in mammalian-adapted PB2 ([@bib32]), can adapt the avian polymerase to function efficiently in mammalian cells. We have suggested that the restriction of avian IAV polymerase is due to a species specific difference in host protein ANP32A ([@bib10]). Avian ANP32A proteins have a 33 amino acid insertion, lacking in mammals, and overexpression of chicken ANP32A (chANP32A) in human cells rescues efficient function of avian origin IAV polymerases ([@bib10]). Removal of the 33 amino acids from chANP32A prevents polymerase rescue, whilst conversely artificial insertion of the 33 amino acids into either huANP32A or B overcomes host restriction ([@bib10]). A naturally occurring splice variant of avian ANP32A lacks the first four amino acids of the 33 amino acid insertion, reducing the rescue efficiency of avian IAV polymerase in human cells ([@bib2]). This may be due to the disruption of a SUMOylation interaction motif, shown to enhance chANP32A's interaction with IAV polymerase ([@bib5]). In human cells, both family members ANP32A and ANP32B (huANP32A/B) are utilised by human adapted IAV polymerases, and are thought to stimulate genome replication from the viral cRNA template, although the exact mechanism remains unclear ([@bib33]).

Here we demonstrate that the avian ANP32B clade is evolutionarily distinct from mammalian and other ANP32Bs. We demonstrate that two amino acids differences, N129 and D130, in the LRR5 domain of chANP32B render it unable to interact with and support IAV polymerase function. We used CRISPR/Cas9 to remove the exon encoding the 33 amino acid insertion from chANP32A or to knockout the entire protein in chicken cells. Edited cells that expressed the short chANP32A isoform lacking the additional 33 amino acids supported mammalian-adapted but not avian IAV polymerase activity. Cells completely lacking chANP32A did not support either mammalian or avian IAV polymerase activity and were resilient to IAV infection. These results suggest a strategy to engineer IAV resilience in poultry through genetic deletion or amino acid changes of the LRR domain of ANP32A protein.

Results {#s2}
=======

Phylogenetic analysis identifies that avian ANP32B is a paralog of mammalian ANP32B {#s2-1}
-----------------------------------------------------------------------------------

To examine the relatedness of ANP32 proteins from different species, we constructed a phylogenetic tree using vertebrate ANP32 protein sequences using *Drosophila* mapmodulin protein as an outgroup. ANP32A and E homologues formed well-supported monophyletic clades which included multiple avian and mammalian species ([Figure 1](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Most vertebrate ANP32B proteins formed a monophyletic clade but this clade did not include avian ANP32B proteins. Rather, avian ANP32B proteins were strongly supported as members of a distinct clade with ANP32C from *Xenopus* and unnamed predicted proteins from non-placental mammals. This suggests that avian ANP32B and mammalian ANP32B are paralogues: birds have lost the protein orthologous to human ANP32B and eutherian mammals have lost the protein orthologous to avian ANP32B. Synteny provides further evidence to support the evolutionary relationship between avian ANP32B, *Xenopus* ANP32C, and the unnamed marsupial gene as they are all found adjacent to ZNF414 and MYO1F on their respective chromosomes ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). In humans, we found a short stretch of sequence between ZNF414 and MY01F which appears homologous to avian ANP32B ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). This provides further evidence that a functional gene orthologous to avian ANP32B has been lost in placental mammals.

![Phylogenetic and sequence analysis reveals avian ANP32B to be a paralog of mammalian ANP32B.\
The best maximum-likelihood tree was calculated from a set of ANP32 proteins with mapmodulin from *Drosophila melanogaster* as an outgroup using RAxML with 100 bootstraps. This figure is a cladogram showing the relationships between mammalian ANP32s, avian ANP32s and ANP32s from *Xenopus tropicalis*. Selected bootstrap values show the relationship between different ANP32 protein clades. Avian ANP32B clade is shown in green. The full tree is shown in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}.](elife-45066-fig1){#fig1}

Chicken ANP32B does not support IAV polymerase activity {#s2-2}
-------------------------------------------------------

We and others have previously shown that both human ANP32A and B proteins support activity of a human-adapted IAV polymerase in human cells ([@bib10]; [@bib33]; [@bib37]). Using CRISPR/Cas9, we generated human eHAP1 cells that lacked expression of both human ANP32A and ANP32B protein (Staller et al. *in review*). In WT eHAP1 cells, human-adapted IAV polymerase (PB2 627K), derived from an H5N1 virus A/turkey/England/50-92/1991 (50-92), was active, whereas the WT avian polymerase (PB2 627E) was not. Exogenous expression of C-terminally FLAG-tagged chANP32A could rescue the activity of avian IAV polymerase whereas expression of chANP32B-FLAG, which naturally lacks the 33 amino acid insertion, did not ([Figure 2a](#fig2){ref-type="fig"}). In double knockout cells, neither human-adapted nor avian-origin polymerase were active. Expression of chANP32A-FLAG rescued activity of both polymerases but expression of chicken ANP32B-FLAG rescued neither, despite confirmation of robust expression by western blot ([Figure 2b and c](#fig2){ref-type="fig"}). This suggests that chicken ANP32B is not functional for IAV polymerase and that the IAV polymerase activity relies on ANP32A in chicken cells. To confirm this in chicken cells, we used CRISPR/Cas9 gene editing to generate chicken DF-1 cells which lacked chANP32B but retained chANP32A expression ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Wild type DF-1 cells had mRNAs for chANP32A, B and E ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) and supported activity of avian IAV polymerase bearing either PB2 627E or 627K. Overexpression of chANP32B-FLAG did not affect activity ([Figure 2d](#fig2){ref-type="fig"}). DF-1 bKO cells also supported activity of both polymerases and again, exogenous expression of chANP32B had no effect. Since chicken cells lacking expression of chANP32B did not demonstrate any loss of IAV polymerase activity compared to WT, this implied that chANP32B is not functional for IAV polymerase and that IAV polymerase uses solely ANP32 family member A in chicken cells.

![Chicken ANP32B is not functional for IAV polymerase.\
Cells were transfected with avian H5N1 50--92 polymerase (PB2 627E or 627K) together with NP, firefly minigenome reporter, *Renilla* expression control, either Empty vector (control) or ANP32 expression plasmid and incubated at 37°C for 24 hr. (**a**) Minigenome assay in human eHAP1 cells with co-expressed Empty vector, FLAG-tagged chANP32A or chANP32B. (**b**) Minigenome assay in double knockout (dKO) eHAP1 cells. (**c**) Western blot analysis of dKO eHAP1 cell minigenome assay confirming expression of PB2 and FLAG-tagged chANP32A and B. (**d**) Minigenome assay in WT DF-1 cells with either co-expressed Empty vector or chANP32B. (**e**) Minigenome assay in DF-1 ANP32B knockout (bKO) cells with either co-expressed Empty vector or chANP32B. Data shown are firefly activity normalised to *Renilla*, plotted as mean ± SEM (n = 3 biological replicates). Two-way ANOVA with Dunnet's multiple comparisons to Empty vector. ns = not significant, \*\*\*\*p\<0.0001.](elife-45066-fig2){#fig2}

Chicken cells lacking intact ANP32A do not support avian IAV polymerase activity {#s2-3}
--------------------------------------------------------------------------------

To investigate the function of ANP32A in chicken cells we utilised a cell type that is more amenable to genome editing and clonal growth. Primordial germ cells (PGCs) are the lineage restricted stem cells which form the gametes in the adult animal. PGCs from the chicken embryo can be easily isolated and cultured indefinitely in defined medium conditions ([@bib35]; [@bib38]). Chicken PGCs can be edited using artificial sequence-specific nucleases and subsequently used to generate genome edited offspring ([@bib20]; [@bib19]). Under appropriate in vitro conditions PGCs can acquire pluripotency and be subsequently differentiated into multiple cell types ([@bib13]; [@bib29]; [@bib28]; [@bib21]). Chicken PGC cells were genome edited using CRISPR/Cas9 and a single guide RNA which generated chANP32A knock-out cells (aKO) containing a biallelic deletion of 8 nucleotides in exon 1. PGCs lacking the 33 amino acid insertion in chANP32A were generated using a pair of guide RNAs to remove exon five resulting in chicken cells with a mammalian-like ANP32A (Δ33) ([Figure 3a](#fig3){ref-type="fig"}). The precise deletions were confirmed by Sanger sequence analysis of subcloned PCR products from genomic DNA, and both found to be homozygous at both alleles ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). We differentiated the edited chicken PGCs into fibroblast-like cells using serum induction with the aim of generating cell lines to test avian IAV polymerase activity ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). The predicted alterations of ANP32A protein in these cells were confirmed by western blot analysis of the PGC-derived fibroblast cells ([Figure 3b](#fig3){ref-type="fig"}). WT, Δ33, and aKO and PGC-derived cell lines were tested for the functional effects of alteration or loss of chANP32A expression on IAV polymerase activity measured by reconstituted minigenome assay. Both avian (PB2 627E) and human-adapted polymerase (PB2 627K) were active in WT fibroblast cells ([Figure 3c](#fig3){ref-type="fig"}). Removal of the 33 amino acids from ANP32A resulted in restriction of the 627E polymerase but not the 627K polymerase, mirroring the avian IAV polymerase phenotype observed in mammalian cells ([@bib10]). Both polymerases were restricted in cells lacking chANP32A (aKO). Expression of exogenous chANP32A in Δ33 and aKO cells rescued avian IAV polymerase activity ([Figure 3d & e](#fig3){ref-type="fig"}) demonstrating the specificity of the genetic alterations. The lack of polymerase activity in the aKO PGC cell line supports the hypothesis that, in the absence of chANP32A, the remaining ANP family members including chANP32B or chANP32E could not support IAV polymerase activity in chicken cells, even though ANP32B and E mRNAs were readily detected in both DF-1 and PGC cells ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

![Chicken PGC derived fibroblast cells lacking ANP32A or the 33 amino acid insertion do not support avian IAV polymerase activity.\
(**a**) Schematic of CRISPR/Cas9 RNA guide targets used to generate aKO (exon1) and Δ33 (exon 5) PGC cell lines. (**b**) Western blot analysis of ANP32A and β-actin expression in WT, KO and Δ33 PGC-derived fibroblast cells. (**c**) Minigenome assay in WT, Δ33 or aKO PGC derived fibroblast cells with either PB2627E (black) or 627K (grey) polymerase derived from avian H5N1 50--92 virus. (**d**) Minigenome assay in WT, Δ33 or aKO cells with avian H5N1 50--92 PB2 627E polymerase co-transfected with Empty vector (black) or FLAG-tagged chANP32A (grey). (**e**) Western blot analysis of PB2, FLAG and Histone 3. Data shown are firefly activity normalised to *Renilla*, plotted as mean ± SEM (n = 3 biological replicates). Two-way ANOVA with Dunnet's multiple comparisons to WT. ns = not significant, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001.](elife-45066-fig3){#fig3}

Functional differences between chicken ANP32A and ANP32B map to the LRR domain sequence {#s2-4}
---------------------------------------------------------------------------------------

ANP32 proteins share a common domain organisation in which an N terminal domain consisting of 5 consecutive leucine rich repeats (LRR 1--5) is followed by a cap and central domain and a C terminal low complexity acidic region (LCAR). In avian ANP32A proteins (except some flightless birds) a sequence duplication, derived in part from nucleotides that encode 27 amino acids (149-175), has resulted in an additional exon and an insertion of up to 33 amino acids between the central domain and the LCAR ([Figure 4a](#fig4){ref-type="fig"}). We previously showed that insertion of the 33 amino acids from the central domain of chANP32A into the equivalent region of the human ANP32A or huANP32B proteins conferred the ability to rescue the activity of a restricted avian IAV polymerase in human cells. The equivalent 33 amino acid insertion into chANP32B (chANP32B^33^) did not support avian IAV polymerase activity ([Figure 4b](#fig4){ref-type="fig"}). In order to ascertain the domains of chANP32B that rendered it non-functional for IAV polymerase activity, we generated chimeric constructs between human and chicken ANP32B. To measure the rescue of avian IAV polymerase in human 293 T cells, all chimeric constructs had the 33 amino acid sequence derived from chANP32A inserted between the LRR and LCAR domains. Western blot analysis and immunofluorescence confirmed that all chimeric constructs were expressed and localised to the cell nucleus as for the wild type ANP32 proteins. ([Figure 4b](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Swapping the LCAR domain of chANP32B into huANP32B^33^ did not prevent the rescue of avian IAV polymerase (huANP32B^33^~LCAR~). Introduction of the central domain of chANP32B into huANP32B (huANP32B^33^~CENT~) significantly reduced rescue efficiency and swapping the LRR domain of chANP32B (huANP32B^33^~LRR~) rendered the protein non-functional to avian IAV polymerase ([Figure 4b](#fig4){ref-type="fig"}). By sequential swapping of each LRR repeat, the 5^th^ LRR of chANP32B was found to be the domain that prevented rescue of avian IAV polymerase ([Figure 4b](#fig4){ref-type="fig"}). The fifth LRR contains five amino acid differences between human and chicken ANP32B, highlighted on the crystal structure of huANP32A, plus an additional one difference to chANP32A ([Figure 4d](#fig4){ref-type="fig"} and [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Swapping chANP32B's fifth LRR into chANP32A also prevented rescue of avian IAV polymerase activity in human cells (chANP32A~LRR5~) ([Figure 4c](#fig4){ref-type="fig"}). Introduction of the single amino acid changes derived from the chANP32B LRR5 sequence into chANP32A revealed that mutations N129I and D130N significantly reduced the ability of chANP32A to rescue avian IAV polymerase activity in human cells ([Figure 4c](#fig4){ref-type="fig"}). Minigenome assays with co-expressed chANP32A or chANP32A~N129I~ in aKO chicken fibroblast cells confirmed that the 129I mutation significantly reduced the ability of chANP32A to support avian-origin (PB2 627E) or human-adapted (PB2 627K) IAV polymerase activity ([Figure 4e](#fig4){ref-type="fig"}).

![Lack of functional support for IAV polymerase by chicken ANP32B maps to differences in LRR5 domain.\
(**a**) Schematic of chicken ANP32A protein highlighting the different domains and LRR sequences (LRR 1--5). (**b**) Human 293 T cells were transfected with avian H5N1 50--92 polymerase (PB2 627E) together with NP, pHOM1-firefly minigenome reporter, *Renilla* expression control, either Empty vector or FLAG-tagged ANP32 expression plasmid and incubated at 37°C for 24 hr. Western blot analysis shown below (FLAG and Vinculin). (**c**) Minigenome assay in 293 T cells (PB2 627E) with FLAG-tagged WT or mutant chANP32A expression plasmids with associated western blot (FLAG and PCNA). (**d**) huANP32A crystal structure (PDB 4 × 05) with residues K116, N127, N129, D130 and K137 highlighted using UCSF Chimaera ([@bib22]). (**e**) Minigenome assay of avian H5N1 50--92 polymerase with either PB2 627E or 627K in PGC-derived fibroblast aKO cells, together with co-expressed Empty vector, chANP32A or chANP32A~N129I~. Data shown are firefly activity normalised to *Renilla*, plotted as mean ± SEM (n = 3 biological replicates). One-way ANOVA with Tukey's comparison to chANP32A (b and c) or two-way ANOVA with Dunnet's multiple comparisons to chANP32A (**e**). ns = not significant, \*p\<0.05, \*\*p\<0.01, \*\*\*\*p\<0.0001.](elife-45066-fig4){#fig4}

Sequence of amino acids 149--175 of the central domain of chANP32A are required to support activity of both avian and human-adapted IAV polymerase {#s2-5}
--------------------------------------------------------------------------------------------------------------------------------------------------

As chANP32A KO PGC-derived fibroblast cells did not support of IAV polymerase despite expressing chANP32B, we were able to use these cells to understand in more detail the sequences in chANP32A required for IAV polymerase activity. The results above showed that the 33 amino acid insertion, fifth LRR and central domain are important for the ability of chANP32A to support function of avian IAV polymerase. We performed the minigenome assay in aKO cells with polymerases containing either PB2 627E and 627K with co-expression of further chANP32 mutants including: chANP32A in which the 27 amino acids in the central domain preceding the 33 amino acid insertion were scrambled (chANP32A~scr149-175~) or chANP32A with the 33 amino acid insertion scrambled (chANP32A~scr176-208~) ([Figure 5a](#fig5){ref-type="fig"}). Both mutants were expressed and localised to the nucleus ([Figure 5c](#fig5){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). The first mutant, chANP32A~scr149-175~, did not support either PB2 627E or 627K polymerase, suggesting the sequence of the central domain is important for function of IAV polymerase. The second mutant, chANP32A ~scr176-208~, only supported PB2 627K function, confirming that the sequence of the 33 amino acid insertion, not just the extended length is required for avian IAV polymerase (PB2 627E) ([Figure 5b](#fig5){ref-type="fig"}).

![Sequence of amino acids 149--175 of the central domain of chANP32A are required to support activity of both avian and human-adapted IAV polymerase.\
(**a**) Schematic of chANP32A showing the sequence of amino acids in the central domain (149--175 or 33 amino acid insertion (176-208) and the randomly scrambled sequence in red. (**b**) Minigenome assay of avian H5N1 50--92 polymerase with either PB2 627E or 627K in PGC-derived fibroblast aKO cells with co-expressed Empty plasmid or FLAG-tagged WT chANP32A, chANP32A~scr149-175~ or chANP32A~scr176-208~ expression plasmids. (**c**) Western blot analysis of PB2 (627E), lamin B1 and FLAG. Data shown are firefly activity normalised to *Renilla*, plotted as mean ± SEM (n = 3 biological replicates). Two-way ANOVA with Dunnet's multiple comparisons to chANP32A. ns = not significant, \*\*\*\*p\<0.0001.](elife-45066-fig5){#fig5}

A single amino acid difference between chANP32B and chANP32A abrogates binding of chANP32A to IAV polymerase {#s2-6}
------------------------------------------------------------------------------------------------------------

An interaction between ANP32A and IAV polymerase was demonstrated previously that is dependent on the presence of all three polymerase subunits (Mistry et al. *in preparation* & [@bib2]; [@bib5]). To examine the interaction between IAV polymerase and chANP32 proteins we employed a split luciferase complementation assay as a quantitative measure of binding ([@bib17]; [@bib4]). The C-terminus of the PB1 subunit of avian origin IAV polymerase was fused with one half of *gaussia* luciferase (PB1^luc1^) and the C-terminus of chicken ANP32A or B with the second half (chANP32A^luc2^ and chANP32B^luc2^) ([Figure 6a](#fig6){ref-type="fig"}). Reconstitution of PB1^luc1^, PB2 and PA together with chANP32A^luc2^ in human 293 T cells gave a strong Normalised Luciferase Ratio (NLR) ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}) with polymerases containing either PB2 627E or 627K ([Figure 6b](#fig6){ref-type="fig"}). Luciferase complementation was significantly less between polymerase and chANP32B^luc2^, and even insertion of the 33 amino acids from chANP32A did not restore the signal (chANP32B~33~^luc2^) ([Figure 6b](#fig6){ref-type="fig"}). When chANP32A carried the single N129I mutation (chANP32A~N129I~^luc2^), luciferase complementation was reduced 22-fold for PB2 627E polymerase and 52-fold forPB2 627K polymerase ([Figure 6c](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). These results suggest that the loss of support of polymerase function by chANP32A~N129I~ was due to a disruption of binding to IAV polymerase.

![A single amino acid change (N129I) derived from chANP32B disrupts chANP32A support of influenza polymerase activity by abrogating binding to IAV polymerase.\
(**a**) Diagram of the split *Gaussia* luciferase system, demonstrating how ANP32 fused to luciferase fragment luc2 may bind to polymerase containing PB1 fused to luciferase fragment luc1 and complement full luciferase, which then reacts with substrate to generate a measurable bioluminescent signal. (**b**) Human 293 T cells were transfected with PB1 fused to luc1 (PB1^luc1^), PB2 (627E or K), PA and either chANP32A, chANP32B or chANP32B~33~ fused to luc2 (control wells were transfected with all components but with unfused PB1 and luc1 or chANP32 and luc2). (**c**) As (**b**) but with either chANP32A^luc2^ or chANP32A~N129I~^luc2^. (**d**) 293 T cells transfected with either chANP32A^luc2^ or chANP32A~N129I~^luc2^ and histone four fused to luc1 (or with unfused controls) or with H4luc1 and histone three fused to luc2. All data are Normalised Luciferase Ratio (n = 3 biological replicates) ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). One-way ANOVA (**d**) or two-way ANOVA with Dunnet's multiple comparisons to chANP32A (b and c). ns = not significant, \*\*\*\*p\<0.0001.](elife-45066-fig6){#fig6}

ANP32A proteins bind to histones as part of their role in chromatin regulation ([@bib26]). To measure if the mutation N129I had any effect on this cellular interaction, we generated expression plasmids that encoded human histone four with luc1 fused to the C-terminus (H4^luc1^) and histone 3.1 with luc2 fused to the C terminus (H3^luc2^). As expected, H4^luc1^ and H3^luc2^ generated a strong NLR, reflecting their interaction in the nucleosome ([@bib11]). The ability of chANP32A to bind histone four was not impaired by mutation N129I, suggesting chANP32~N129I~ was not altered in this cellular role, despite abrogation of its support of IAV polymerase ([Figure 6d](#fig6){ref-type="fig"}).

Viral replication is abrogated in chicken cells lacking ANP32A {#s2-7}
--------------------------------------------------------------

The data above suggest that chANP32B cannot substitute for chANP32A in support of IAV polymerase in chicken cells. Since chicken cells that completely lack expression of chANP32A show no polymerase activity in the minigenome assay, they might be refractory to IAV infection. Multi-cycle growth kinetics of recombinant influenza A viruses were measured in WT and aKO PGC-derived fibroblast cells ([Figure 7](#fig7){ref-type="fig"}). To ensure robust infection, recombinant viruses were generated carrying H1N1 vaccine strain PR8 haemagglutinin (HA), neuraminidase (NA) and M genes; this also mitigated the risks of working with avian influenza viruses with novel antigenicity. Infectious titres of recombinant virus with internal genes of avian H5N1 virus 50--92 were not detected in the chicken cells lacking ANP32A infected at low MOI ([Figure 7a](#fig7){ref-type="fig"}). At higher MOI virus titres were significantly reduced compared to WT chicken cells, almost 325-fold less at 8 hr post infection and 16-fold less by 24 hr ([Figure 7c](#fig7){ref-type="fig"}). Similarly, at low MOI, a recombinant virus with internal genes from the H7N9 virus A/Anhui/1/2013, had limited virus growth in aKO cells but replicated efficiently in WT fibroblasts ([Figure 7b](#fig7){ref-type="fig"}). At the higher MOI, peak viral titres were 1365-fold less than in WT cells at 8 hr post infection and 100-fold less by 24 hr ([Figure 7d](#fig7){ref-type="fig"}). Since virus growth in aKO cells was observed at the higher MOI, we sequenced the PB2 gene of virus progeny to determine if this replication was due to adaptation in PB2. At 24 hr post infection the sequence of the PB2 gene from virus in supernatants of cells infected at high MOI was determined. Virus recovered from aKO and WT cells was found to be identical and contained no sequence changes compared with the inoculum, suggesting adaptation in PB2 was not required for the low level of replication seen in the aKO cells. In conclusion, PGC derived fibroblast cells lacking chANP32A were resilient to IAV replication, particularly at lower multiplicities of infection.

![Viral replication is abrogated in chicken PGC fibroblast cells lacking ANP32A.\
WT (black lines) or aKO (red lines) PGC-derived fibroblast cells were infected with recombinant viruses (containing PR8 HA, NA and M genes and internal genes from either H5N1 50--92 or H7N9 Anhui), at an MOI of either 0.0001 (**a,b**) or 1.0 (**c,d**), incubated at 37°C in the presence of trypsin, cell supernatants harvested at described time-points and PFU ml^−1^ measured by plaque assay on MDCK cells. (**a**) H5N1 50--92 (MOI 0.0001). b. H7N9 Anhui (MOI 0.0001). c. H5N1 50-−92 (MOI 1.0). d. H7N9 Anhui (MOI 1.0). vRNAs from supernatants 24 hr post infection MOI 1.0 (c and d) were extracted, PCR amplified and sequenced by Sanger sequencing. Limit of detection by plaque assay shown by dotted line (10PFU ml^−1^). n = 3 biological replicates. Multiple t-tests with Holm-Sidak comparison. ns = not significant, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001.](elife-45066-fig7){#fig7}

Discussion {#s3}
==========

We show that avian origin IAV polymerases rely exclusively on chicken ANP32A family member for their replication, because they are unable to co-opt chicken ANP32B. We found avian ANP32B proteins formed a separate phylogenetic group from other ANP32Bs ([Figure 1](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Synteny demonstrated that an avian ANP32B homologue was present in coelacanth, amphibians and non-placental mammals as these loci were identical to the ANP32B locus in birds ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). A functional avian ANP32B homologue has been lost in placental mammals although a very small part of an ANP32 gene remained in humans ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Human ANP32C is an intronless gene that is most closely related to ANP32A ([@bib26]) and is unrelated to the avian ANP32B clade. There was no evidence found of a mammalian ANP32B homologue in birds.

Chicken ANP32B could not support influenza polymerase function due to an amino acid difference in LRR5 at residue 129 that adversely affected the interaction between chANP32B and influenza polymerase ([Figure 6](#fig6){ref-type="fig"}). Other avian ANP32B proteins, including those of duck and turkey, carry isoleucine at residue 129 suggesting that our findings may also be applicable to other avian hosts ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). The replacement of the exposed polar residue, asparagine (N129) with the hydrophobic isoleucine (I) may have led to the disruption of a key electrostatic interaction between ANP32A and the virus polymerase complex. In addition to the residue 129I, the central domain (amino acids 141--175) of chANP32B also contributed to its poor efficiency at rescuing avian IAV polymerase function in human cells ([Figure 4](#fig4){ref-type="fig"}). This, together with the observation that scrambling amino acids 149--175 in chANP32A prevented both human-adapted and avian IAV polymerase function ([Figure 4](#fig4){ref-type="fig"}) suggests that LRR5 and the central domain of ANP32A are crucial to IAV polymerase function. Our finding that chANP32B is non-functional for IAV polymerase was recently corroborated by another research group; this preliminary work also found that this phenotype mapped to residues 129I and 130N of chANP32B ([@bib39]). The observation that scrambling the 33-amino acid insertion prevented avian IAV polymerase rescue ([Figure 5](#fig5){ref-type="fig"}) is consistent with results from by Domingues and Hale and Baker and colleagues which showed that the SUMO Interaction motif (SIM)-like sequence present in the 33 amino acid insertion (VLSLV), was required for strong binding to both 627E and 627K polymerase and its deletion or mutation decreased its ability to support avian IAV polymerase activity in human cells ([@bib2]; [@bib5]). Understanding the domains important to binding and function may help us understand the mechanism by which ANP32A or B support IAV polymerase which is still not fully elucidated ([@bib33]).

Chicken cells lacking ANP32A did not support activity of avian or human-adapted IAV polymerase in minigenome assay ([Figure 2](#fig2){ref-type="fig"}). However, at higher MOI, virus replication was observed in aKO cells, although still significantly lower than in WT PGC cells ([Figure 7c&d](#fig7){ref-type="fig"}). This implies some IAV polymerase function, albeit inefficient, in the absence of chANP32A in the context of virus infection. Other viral products present during virus infection such as NEP may partly compensate for the block in replication in cells that lack chANP32A. Indeed NEP expression has been reported to rescue avian polymerase replication in human cells ([@bib12]). Nonetheless the significantly reduced level of virus replication observed in the chicken cells that lack chANP32A in vitro implies that in vivo, chickens that do not express ANP32A or express altered protein may be resilient to infection by IAV. It will be pertinent to investigate whether IAV can evolve to replicate in chicken cells that lack or express a mutated ANP32A although no adaptation of PB2 gene was observed here. The discrepancy between the lack of polymerase activity in the minigenome assay in absence of ANP32A yet limited replication observed using infectious virus in the same cells may ultimately reveal interesting insights about how ANP32A supports polymerase. The use of the PGC-derived chicken cells to investigate a host factor essential for virus raises the possibility of generating genome-edited chicken models resistant or resilient to infection. Chicken PGCs can be efficiently genome-edited to generate specific haplotypes ([@bib7]). Our novel method of chicken PGC differentiation into fibroblast-like cells enabled robust testing of a defined genotype, and will permit future investigation of other host genetic factors identified through forward genetic screens and suspected to play important roles in virus infections ([@bib30]; [@bib36]). We demonstrated that a mutated chANP32A was able to bind histone 4, suggesting this cellular role may not be affected by amino acid change at 129. However, there are many roles attributed to ANP32A proteins in the cell, such as embryogenesis, and disruption of these functions may limit the ability to generate healthy gene-edited animals ([@bib26]; [@bib25]).

In summary, we provide evidence that specific domains of ANP32 proteins are important for the function of IAV polymerases and describe a lack of redundancy in the involvement of ANP32 family members to support IAV polymerase complex in chicken cells that is determined by the variation in ANP32 protein sequences. These data may aid in the design of novel small molecule inhibitors that disrupt the ANP32-polymerase interface and form the basis of a potential pathway for the generation of influenza virus resilient animals.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                   Designation                                      Source or\                                                                                Identifiers                                                                         Additional\
  (species) or\                                                                    reference                                                                                                                                                                     information
  resource                                                                                                                                                                                                                                                       
  ------------------------------- ------------------------------------------------ ----------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------- ----------------------------------------------------------
  Genetic reagent (*G. gallus*)   GFP^+^/Hyline cross                              Roslin Institute                                                                                                                                                              Fertile heterozygous eggs for PGC derivations ([@bib22])

  Primary cells (*G. gallus*)     Primordial Germ Cells (PGCs)                     *G. gallus* GFP^+^/Hyline cross, Roslin Institute (This study)                                                                                                                

  Cell line (*G. gallus*)         DF-1 fibroblasts                                 American Type Culture Collection                                                          CRL-12203; RRID:[CVCL_0570](https://scicrunch.org/resolver/CVCL_0570)               

  Cell line (*C. sapiens*)        MDCK                                             American Type Culture Collection                                                          CCL- 34; RRID:[CVCL_0422](https://scicrunch.org/resolver/CVCL_0422)                 

  Cell line (*H. sapiens*)        293T                                             American Type Culture Collection                                                          CRL-3216; RRID:[CVCL_0063](https://scicrunch.org/resolver/CVCL_0063)                

  Cell line (*H. sapiens*)        eHAP1                                            Horizon Discovery                                                                         C669                                                                                

  Antibody                        rabbit polyclonal α-ANP32A                       Sigma-Aldrich                                                                             AV40203; RRID:[AB_1844874](https://scicrunch.org/resolver/AB_1844874)               Dilution 1:500-1:1000

  Antibody                        mouse monoclonal α-β-actin                       Sigma-Aldrich                                                                             A2228; RRID:[AB_476697](https://scicrunch.org/resolver/AB_476697)                   Dilution 1:1000

  Antibody                        mouse monoclonal α-FLAG                          Sigma-Aldrich                                                                             F1804; RRID:[AB_262044](https://scicrunch.org/resolver/AB_262044)                   Dilution 1:1000 (WB), 1:300 (IF)

  Antibody                        mouse monoclonal α-Lamin B1                      Merck                                                                                     MAB5492; RRID:[AB_2085944](https://scicrunch.org/resolver/AB_2085944)               Dilution 1:1000

  Antibody                        mouse monoclonal α-PCNA                          Santa Cruz                                                                                sc-25280, RRID:[AB_628109](https://scicrunch.org/resolver/AB_628109)                Dilution 1:1000

  Antibody                        rabbit polyclonal α-Histone 3                    Abcam                                                                                     AB1791; RRID:[AB_302613](https://scicrunch.org/resolver/AB_302613)                  Dilution 1:2000

  Antibody                        rabbit monoclonal α-vinculin                     Abcam                                                                                     AB129002; RRID:[AB_11144129](https://scicrunch.org/resolver/AB_11144129)            Dilution 1:1000

  Antibody                        rabbit polyclonal α-Gaussia Luc                  NEB                                                                                       E80235                                                                              Dilution 1:2000

  Antibody                        rabbit polyclonal α-PB1                          Invitrogen                                                                                PA5-34914; RRID:[AB_2552264](https://scicrunch.org/resolver/AB_2552264)             Dilution 1:2000

  Antibody                        rabbit polyclonal α-PB2                          GeneTex                                                                                   GTX125926; RRID:[AB_11162999](https://scicrunch.org/resolver/AB_11162999)           Dilution 1:2000

  Antibody                        goat polyclonal anti-rabbit HRP                  CST                                                                                       7074                                                                                Dilution 1:2000

  Antibody                        Horse polyclonal anti-mouse HRP                  CST                                                                                       7076                                                                                Dilution 1:2000

  Antibody                        Sheep polyclonal α-rabbit HRP                    Merck                                                                                     AP510P                                                                              Dilution 1:20000

  Antibody                        goat polyclonal α-mouse HRP                      AbD Serotec                                                                               STAR117P; RRID:[AB_323839](https://scicrunch.org/resolver/AB_323839)                Dilution 1:10000

  Antibody                        goat polyconal α-mouse AlexaFluor-568            Invitrogen                                                                                A11031; RRID:[AB_144696](https://scicrunch.org/resolver/AB_144696)                  Dilution 1:1000

  Recombinant DNA reagent         pGEM-T Easy vector                               Promega                                                                                   A1360                                                                               

  Recombinant DNA reagent         pSpCas9(BB)−2A-Puro PX459 V2.0 vector            Gift from Dr. Feng Zhang                                                                  RRID:[Addgene_62988](https://scicrunch.org/resolver/Addgene_62988)                  

  Recombinant DNA reagent         pSpCas9n(BB)−2A-GFP PX461 vecotr                 addgene                                                                                   Plasmid 48140; RRID:[Addgene_48140](https://scicrunch.org/resolver/Addgene_48140)   

  Recombinant DNA reagent         pCAGGS vector                                    Belgium Co-ordinated Collections of Microorganisms (BCCM), University of Ghent, Belgium                                                                                       

  Recombinant DNA reagent         H5N1 A/turkey/England/50-92/1991 polI plasmids   APHA, Weybridge, UK                                                                                                                                                           

  Recombinant DNA reagent         H7N9 Anhui/1/2013 pHW2000 plasmids               Pirbright Institute, UK                                                                                                                                                       

  Recombinant DNA reagent         H1N1 A/PR/8/34 (PR8) polI or pHW2000 plasmids    ([@bib18])                                                                                                                                                                    

  Commercial assay or kit         RNeasy mini kit                                  Qiagen                                                                                    74106                                                                               

  Commercial assay or kit         Quick Start Bradford Protein Assay Kit           Biorad                                                                                    5000202                                                                             

  Commercial assay or kit         Dual-luciferase Reporter assay system            Promega                                                                                   E1910                                                                               

  Commercial assay or kit         Renilla luciferase kit                           Promega                                                                                   E2810                                                                               

  Commercial\                     QIAamp Viral RNA Mini Kit                        Qiagen                                                                                    52906                                                                               
  assay or kit                                                                                                                                                                                                                                                   

  Chemical compound, drug         Lipofectamine 3000                               Invitrogen                                                                                L3000008                                                                            

  Chemical\                       Lipofectamine 2000                               Invitrogen                                                                                11668019                                                                            
  compound, drug                                                                                                                                                                                                                                                 

  Software, algorithm             Image J                                          ImageJ (<http://imagej.nih.gov/ij/>)                                                                                                                                          

  Software, algorithm             GraphPad Prism                                   GraphPad Prism (<https://graphpad.com>)                                                   version 6                                                                           

  Software, algorithm             Geneious                                         Geneious <https://www.geneious.com>                                                       R6                                                                                  
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Animal use {#s4-1}
----------

The GFP^+^ PGCs used in the experiments were obtained by crossing the Roslin Green (ubiquitous GFP) line of transgenic chickens with a flock of commercial Hyline layer hens maintained at the Roslin Institute to produce heterozygous fertile eggs for PGC derivations ([@bib22]). Commercial and transgenic chicken lines were maintained and bred under UK Home Office License. All experiments were performed in accordance with relevant UK Home Office guidelines and regulations. The experimental protocol and studies were reviewed by the Roslin Institute Animal Welfare and Ethical Review Board (AWERB) Committee. Chickens for egg production were maintained under the HO code of practice (ISBN 9781474112390).

Plasmid constructs {#s4-2}
------------------

ANP32A guide RNAs (gRNA) were designed using CHOPCHOP gRNA web tool (<http://chopchop.cbu.uib.no/>) ([@bib16]; [@bib8]). gRNA 5'-CGGCCATGGACATGAAGAAA-3' targeting ANP32A exon1, and gRNAs: 5'-AGCTGGAAGCAATATGTACT-3' and 5'-CATTCCCCTCGCTCCTTCAA-3' targeting either side of exon 5 (Δ33 PGC cells) were cloned into pSpCas9(BB)−2A-Puro (pX459 v2.0; a gift from Dr. Feng Zhang) using Materials and methods described by previously ([@bib23]). For DF-1 ANP32B gRNAs, the guides 5'-TTCAGATGATGGGAAGATCG-3' and 5'-GGTTCTCAAAATCTGAAGAG-3' were cloned into the double 'nickase' vectors pSpCas9n(BB)−2A-GFP (pX461) and pSpCas9n(BB)−2A-Puro (pX462) respectively ([@bib23] ; [@bib24]).

*Gaussia* luc1 and luc2 were generated by gene synthesis (GeneArt, ThermoFisher) using the sequence previously described ([@bib4]). *Homo sapiens* Histone 4 (NP_003533.1) and 3.1 (NP_003520.1) were generated gene synthesis (GeneArt, ThermoFisher). Luc1 or luc2 were added to the C-termini of ANP32, PB1, H4 or H3.1 using the linker sequence, AAAGGGGSGGGGS, by overlapping PCR. The 33 amino acid insertion was added to huANP32B after residue 173 and to chANP32B after residue 181 (preserving an acid region before SIM motif \[[@bib5]\]). The LRR (amino acids 1--149), central domain (amino acids 150--175) or LCAR (amino acids 176--262) from chANP32B were swapped into huANP32B~33~ to generate chimeric constructs. ANP32 constructs were made by overlapping PCR or by gene synthesis (GeneArt, ThermoFisher) with either a FLAG tagged fused to the C-terminus with a GSG linker or to mCherry with a GSGGGSGG linker.

Cells and cell culture {#s4-3}
----------------------

Human embryonic kidney (293T) (ATCC) and Madin-Darby canine kidney (MDCK) cells (ATCC) were maintained in cell culture media (Dulbecco's modified Eagle's medium (DMEM; Invitrogen) supplemented with 10% fetal calf serum (FCS) (Biosera), 1% non-essential amino acids (NEAA) and with 1% penicillin-streptomycin (Invitrogen)) and maintained at 37°C in a 5% CO2 atmosphere. Human eHAP1 cells (Horizon Discovery) were cultured in Iscove's Modified Dulbecco's Medium (IMDM) supplemented with 10% fetal bovine serum (FBS), 1% NEAAs, and 1% penicillin/streptomycin. Chicken fibroblast (DF-1) (ATCC) cells were maintained in DF-1 cell culture media (DMEM supplemented with 10% FCS, 5% tryptose phosphate broth (Sigma-Aldrich), 1% NEAAs and 1% penicillin-streptomycin and maintained at 39°C in a 5% CO2 atmosphere. Cell line authentication: DF-1, eHAP1 and 293 T cells were authenticated by mRNA analysis confirming the relevant species. All continuous cell lines were routinely screened for mycoplasma contamination and were mycoplasma free.

PGC, DF-1 and eHAP1 cell line generation {#s4-4}
----------------------------------------

PGCs were derived and cultured in FAOT medium as previously described ([@bib38]). PGCs were transiently transfected with 1.5 µg of PX459 V2.0 vector using Lipofectamine 2000 (Invitrogen) and treated with puromycin as previously described ([@bib7]). Subsequently, single cell cultures of puromycin-resistant cells were established to generate clonal populations for downstream experiments as previously described in [@bib7]. To identify an ANP32A Δ33 PGC cell line, PCR products were directly sequenced using PCR primers to analyse mutation genotypes of isolated single cell clones. To identify an ANP32A KO PGC cell line, PCR products were cloned into pGEM-T Easy vector (Promega) and sequenced using T7 promoter forward primer by Sanger sequencing. DF-1 cells were transfected with the described CRISPR/Cas9 constructs using Lipofectamine 2000 (Invitrogen) and subject to puromycin selection. Single cell clones were expanded and analysed by PCR of genomic DNA and Sanger sequencing using primers (5'-TTTTTGCTTACATCTGAGGGC-3', 5'-CCTCCGCAGTTATCAGGTTAGT-3') for ANP32A exon1, (5'-GCTCCCTGGTCTGCTAGTTAT-3', 5'-GGTCTACGCAACCACACATAC-3') for ANP32A exon five and (5'-CCCTTAAGGTGAGCACAGGG-3', 5'-AACATAGCACCACTCCCAGC-3') for ANP32B exon2. eHAP1 dKO cells were generated as described (Staller et al. *in review*).

Differentiation of PGCs into adherent fibroblast-like cells (PGC derived fibroblasts) {#s4-5}
-------------------------------------------------------------------------------------

PGCs were cultured in 500 µl of high calcium FAOT medium containing 1.8 mM CaCl~2~ in fibronectin-coated wells (24-well plate) for 48 hr ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}) ([@bib38]). Subsequently, PGCs were transferred into PGC fibroblast medium and then refreshed every 48 hr by removing and replacing with 300 µl of PGC fibroblast cell culture medium. Adherent fibroblast-like cells were observed within 72 hr. Cells were then refed every two days and split 1:4 every four days. PGC fibroblast cell cultures were expanded to 85--90% confluency in 24-well plates before using for transfection, infection or western blot analysis. PGC fibroblast cells were maintained in cell culture media (Knockout DMEM (10829018, Gibco) with 10% ES grade FBS (16141061, Invitrogen), 1% chicken serum (Biosera), 0.1% 100xNEAA (Gibco), 0.1% Pyruvate (11360070, Gibco), 0.1% 100xGlutamax (Gibco: 35050--038), 0.5 mg ml^−1^ ovotransferin (C7786, Sigma)) and 1% penicillin-streptomycin at 37°C with 5% CO~2~.

Influenza A virus infection {#s4-6}
---------------------------

Recombinant influenza A PR8 (A/PR/8/34 (H1N1)) 3:5 reassortant virus (PR8 HA, NA and M genes with PB1, PB2, PA, NP and NS genes from A/Anhui/1/13 (H7N9) was generated by reverse genetics at The Pirbright Institute, UK. Reverse genetics virus rescue was performed by transfection of Human Embryonic Kidney (HEK) 293 T cells (ATCC) with eight bi-directional pHW2000 plasmids containing the appropriate influenza A virus segments and co-culture in MDCK cells (ATCC) with addition of 2 µg ml^−1^ of TPCK treated Trypsin (Sigma-Aldrich). Rescued viruses were passaged once in embryonated hen's eggs to generate working stocks. Recombinant PR8 3:5 reassortant 50--92 (A/turkey/England/50-92/1991 (H5N1) was described previously \[[@bib9]\]).

Virus was diluted in Knockout DMEM and incubated on PGC fibroblast cells for 1 hr at 37°C (MOI as indicated in the relevant figure legends) after which inoculum was removed and cells washed with PBS followed by MES buffer (pH 4, 37°C) for five mins and a further PBS wash. Infection media (Knockout DMEM (10829018, Gibco), 0.14% BSA and 1 μg ml^−1^ TPCK trypsin (Sigma-Aldrich)) wash added and cells were incubated at 37°C. To ensure residual virus was removed, a 0 hr time point was taken. Cell supernatants were harvested and stored at −80°C. Infectious titres were determined by plaque assay on MDCK cells.

vRNA extraction from cell supernatants was performed using QIAamp Viral RNA Mini Kit (Qiagen 52906). First strand synthesis was performed using SuperScript IV reverse transcriptase with primer 5'-GCAGGTCAAATATATTCAATATGG-3'. cDNA was amplified using KOD Hot Start DNA polymerase (Merck 71086) using primers 5'-GCAGGTCAAATATATTCAATATGG-3' and 5'-GGTCGTTTTTAAACAATTCGAC-3' and the PCR product was sequenced by Sanger sequencing.

Minigenome assay {#s4-7}
----------------

Influenza polymerase activity was measured by use of a minigenome reporter which contains the firefly luciferase gene flanked by the non-coding regions of the influenza NS gene segment, transcribed from a species-specific polI plasmid with a mouse terminator sequence. The human and chicken polI minigenomes (pHOM1-Firefly and pCOM1-Firefly) are described previously ([@bib15]). pCAGGS expression plasmids encoding each polymerase component and NP for 50--92 (H5N1 A/Turkey/England/50--92/91) are described previously ([@bib9]). To measure influenza polymerase activity, 293 T cells were transfected in 48-well plates with pCAGGS plasmids encoding the PB1 (20 ng), PB2 (20 ng), PA (10 ng) and NP (40 ng) proteins, together with 20 ng species-specific minigenome reporter, either Empty pCAGGS or pCAGGS expressing ANP32 (50 ng) and, as an internal control, 10 ng Renilla luciferase expression plasmid (pCAGGS-Renilla), using Lipofectamine 3000 transfection reagent (Invitrogen) according to manufacturers' instructions. DF-1 and PGC fibroblast cells were transfected as 293 T cells but with twice the concentration of DNA. Cells were incubated at 37°C. 20--24 hr after transfection, cells were lysed with 50 μl of passive lysis buffer (Promega), and firefly and Renilla luciferase bioluminescence was measured using a Dual-luciferase system (Promega) with a FLUOstar Omega plate reader (BMG Labtech).

Split luciferase assay {#s4-8}
----------------------

293 T cells were transfected with PB1^luc1^ (25 ng), either PB2 627E or PB2 627K (25 ng), PA (12.5 ng) and chANP32A^luc2^, chANP32AN129I^luc2^, chANP32B^luc2^ or chANP32B~33~^luc2^ (12.5 ng). For split luciferase assays measuring histone interaction, 50 ng of either chANP32A^luc2^, chANP32AN129I^luc2^, H4^luc1^ or H3^luc2^ were transfected into 293 T cells. Control samples assessed the interaction between H4 or PB1^luc1^ and an untagged luc2 construct or the appropriate ANP32A^luc2^ construct and an untagged luc1 construct. All other components transfected into control samples remained consistent with those transfected in with the interacting proteins of interest. 24 hr after transfection, cells were lysed in 50 ul Renilla lysis buffer (Promega) for one hour at room temperature. *Gaussia* luciferase activity was then measured from 10 ul of lysate using the Renilla luciferase kit (Promega) with a FLUOstar Omega plate reader (BMG Labtech). Normalised luminescence ratios were calculated by dividing the luminescence measured from the interacting partners by the sum of the interaction measured from the two controls for each sample ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}) as previously described ([@bib4]).

Immunoblot analysis {#s4-9}
-------------------

For analysis of PGC derived fibroblasts ([Figure 3b](#fig3){ref-type="fig"}), at least 300,000 cells were lysed in 60 µl of 1X RIPA lysis buffer (sc-24948, Santa Cruz Biotechnology) according to the manufacturer's instruction. Protein concentration was determined using the Bradford method with the Quick Start Bradford Protein Assay Kit (\#5000202, BIORAD) according to the manufacturer's instruction ([@bib3]) Denaturing electrophoresis and western blotting were performed using the NuPAGE electrophoresis system (Invitrogen) following the manufacturer's protocol. For all other Western blots, cells were lysed in lysis buffer (50 mM Tris-HCl pH 7.8 (Sigma Aldrich), 100 mM NaCl, 50 mM KCl and 0.5% Triton X-100 (Sigma Aldrich), supplemented with cOmplete EDTA free Protease inhibitor cocktail tablet (Roche)) and prepared in Laemmli 2 × buffer (Sigma-Aldrich). Cell proteins were resolved by SDS--PAGE using Mini-PROTEAN TGX Precast Gels (Bio-Rad). Immunoblotting was carried out using the following primary antibodies: rabbit α-ANP32A (Sigma-Aldrich AV40203), mouse α-β-actin (Sigma-Aldrich A2228), mouse α-FLAG (F1804, Sigma-Aldrich), mouse α-Lamin B1 (MAB5492, Merck), mouse α-PCNA (sc-25280, Santa Cruz), rabbit α-Histone 3 (AB1791, Abcam), rabbit α-vinculin (AB129002, Abcam), rabbit α-*Gaussia* Luc (E80235, NEB), rabbit α-PB1 (PA5-34914, Invitrogen) and rabbit α-PB2 (GTX125926, GeneTex). The following secondary antibodies were used: goat anti-rabbit HRP (CST \#7074), anti-mouse HRP (CST \#7076), goat α-mouse AlexaFluor-568 (A11031, Invitrogen), sheep α-rabbit HRP (AP510P, Merck) and goat α-mouse HRP (STAR117P, AbD Serotec). Protein bands were visualised by chemiluminescence (ECL +western blotting substrate, Pierce) using a FUSION-FX imaging system (Vilber Lourmat).

Quantification of chANP32A, B and E mRNA levels {#s4-10}
-----------------------------------------------

Total RNA from PGC fibroblast and DF-1 cells were extracted using an RNeasy mini kit (Qiagen), following manufacturer's instructions. During extraction of RNA, RNeasy columns were treated with RNase-Free DNase (Qiagen). RNA samples were quantified using a Nanodrop Spectrophotometer (Thermo Scientific). Equal concentrations of RNA were subject to first strand synthesis using RevertAid (Thermo Scientific) with Oligo(dT) (Thermo Scientific). This product was then quantified with Fast SYBR Green Master Mix (Thermo Scientific) using the following sequence-specific primer pairs: RS17, (5'-ACACCCGTCTGGGCAACGACT-3' and 5'-CCCGCTGGATGCGCTTCATCA-3'), RPL30 (5'-CCAACAACTGTCCTGCTTT-3' and 5'-GAGTCACCTGGGTCAATAA-3'), chANP32A (5′-GTTTGCAACTGAGGCTAAGC-3′ and 5'-CAACTGTAGGTCATACGAAGGC-3'), chANP32B (5′- GGTGGCCTTGAAGTTCTAGC-3′, and 5'-ATGAGCATCGTCACCTCGC-3'), chANP32E (5'- GAACTAGAGTTTCTTAGCATGG-3' and 5'- TCTCTCTGCAAGGACCTCCAG-3'). Real-time quantitative PCR analysis was performed (Applied Biosystems ViiA 7 Real-Time PCR System).

Safety/biosecurity {#s4-11}
------------------

All work with infectious agents was conducted in biosafety level two facilities, approved by the Health and Safety Executive of the UK and in accordance with local rules, at Imperial College London, UK.

Bioinformatics {#s4-12}
--------------

ANP32 sequences were downloaded from Ensembl (Gene Trees ENSGT00940000153254 and ENSGT00940000154305.) Amino acid sequences were aligned using MUSCLE ([@bib6]) and the maximum likelihood tree was constructed using RAxML-HPC2 v.8.2.10 ([@bib31]) (GTRGAMMA model, 100 bootstraps) on XSEDE run on CIPRES ([@bib14]). Mapmodulin from *Drosophila melanogaster* was used as an outgroup.

Statistical analysis was performed using GraphPad Prism v.7. Sequencing data was analysed using Geneious Sorfware R6. Image analysis was done using Image J and Microsoft Office 2016.
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The data used to generate Figure 1 and Figure 1- figure supplement 1 was downloaded from Ensembl (<http://www.ensembl.org/Multi/GeneTree/Image?gt=ENSGT00950000182907>). Source data for Figures 2, 3, 4, 5, 6 & 7 are available on Dyrad <https://dx.doi.org/10.5061/dryad.338t920>.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Species specific differences in use of ANP32 proteins by influenza A virus\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a guest Reviewing Editor and Patricia Wittkopp as the Senior Editor. The following individual involved in review of your submission has agreed to reveal his identity: Benjamin G Hale (Reviewer \#1).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Human ANP32A and ANP32B are important polymerase cofactors of influenza viruses. Avian influenza virus relies exclusively on avian ANP32A, thereby defining the host range of influenza virus and is dependent upon a duplication in ANP32A that is unique to birds. In this work the authors could show that human and avian ANP32B are paralogues with a different evolutionary history. Using a series of genomic deletions or mutations in human and avian cells, they show that influenza polymerase is effectively non-functional in human cells lacking both ANP32A and B, whereas deletion of only ANP32A in chicken cells yields the same phenotype. In complementation experiments, the authors could further show that ANP32B cannot stimulate polymerase activity and that only two amino acid variants common to avian ANP32B render it non-functional for the viral polymerase. Intriguingly, viral replication is severely impaired in chicken cells where ANP32A is knocked out, leading the authors to propose that genetic modification of chickens could serve as a bio-control for influenza virus.

Essential revisions:

1\) The authors propose that \"avian ANP32B and mammalian ANP32B are paralogues: birds have lost the protein orthologous to human ANP32B and eutherian mammals have lost the protein orthologous to avian ANP32B\". This is based on the phylogenetic relationships, that suggest that avian ANP32B and mammalian ANP32B shared a common ancestor gene that derived these proteins by duplication, and then one was lost in avian and the other in mammals. If this is the case, it is likely that avian have the remains of a non functional mammalian ANP32B, and mammals the remains of a non functional avian ANP32B (or ANP32C, its orthologue). Are these pseudogenes found in the genome of mammals and birds? The authors indicate in the discussion that this is the case for humans, but no mention in birds is given.

2\) The way the manuscript is written and the data presented are a bit misleading. At the end, the story is that ANP32A, ANP32B and ANP32C are paralogues. Only ANP32A and ANP32B support influenza polymerase replication, with some species-specificity depending on polymerase polymorphisms. ANP32B is not found in avian, and the so called avian ANP32B is in reality ANP32C, and therefore, avian species only have ANP32A to support influenza polymerase activity, as they lack ANP32B. The authors should re-write the Abstract and some of the portions of the manuscript to make this point clear.

3\) Although is clear the deletion or alteration of chicken ANP32A make chicken cells resistant to optimal replication with influenza virus, the authors cannot exclude that if mutations are introduced in chicken that abrogate the ability of ANP32A to promote virus replication, this result in a selective pressure that select for mutant influenza viruses able to use avian ANP32B or mutated avian ANP32A. This should be discussed.

4\) The authors conclude that PGC aKO are \"effectively resistant\" to influenza virus replication. Yet, Figure 7 shows clear low-level titres that persist throughout the infection and these are noted in the Discussion (paragraph three). A more rigorous assessment is needed to know if these cells support viral replication, both in low MOI multi-cycle and high MOI single-cycle infections. While this could appear to be a semantic distinction, it is critically important for their proposed use of aKO as a bio-control. Any level of viral replication in aKO cells raises the possibility that the virus will adapt, possibly by acquiring the ability to utilise ANP32B. Do viruses recovered at 48hr contain any novel mutations, especially in 7a or 7c-d where titres persist or even increase at later times?

5\) The authors propose using aKO in chickens as a means to control influenza virus replication. While a potentially interesting approach, the current data limit confidence in this conclusion. Influenza virus rapidly adapts to diverse host environments, with as little as a single amino acid change in the polymerase conveying new functionality in using different ANP32 proteins. It would seem likely that adaptive variants would arise under these conditions. Moreover, knock-out analysis in mice shows that ANP32A plays an important role in embryogenesis, and that this is more pronounced in the absence of ANP32B (Reilly et al., 2011). Will this also occur in chickens, which naturally lack a true ANP32B paralog and where the newly-named ANP32C is nonfunctional in at least its ability to support IAV polymerases? A more tempered and nuanced discussion of the potential of aKOs is warranted.
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Author response

> Essential revisions:
>
> 1\) The authors propose that \"avian ANP32B and mammalian ANP32B are paralogues: birds have lost the protein orthologous to human ANP32B and eutherian mammals have lost the protein orthologous to avian ANP32B\". This is based on the phylogenetic relationships, that suggest that avian ANP32B and mammalian ANP32B shared a common ancestor gene that derived these proteins by duplication, and then one was lost in avian and the other in mammals. If this is the case, it is likely that avian have the remains of a non functional mammalian ANP32B, and mammals the remains of a non functional avian ANP32B (or ANP32C, its orthologue). Are these pseudogenes found in the genome of mammals and birds? The authors indicate in the Discussion that this is the case for humans, but no mention in birds is given.

The presence of both ANP32B and ANP32C in *Xenopus* and orthologous genes in marsupial mammals strongly suggests that both these genes were present in the common ancestor of mammals and birds. Subsequently, ANP32C was lost in the ancestor of placental mammals and ANP32B was lost in the ancestor of birds. The reviewers suggest that the remains of ANP32C should be found in mammals and ANP32B should be found in birds. We have searched more extensively for evidence of these genes. For humans, the synteny surrounding where a gene orthologous to avian ANP32B should be is the same as in marsupials. There is a small amount of evidence that there are remnants of what would have been an ANP32 gene still present in humans: specifically, LRR3 of avian ANP32B maps to the human genome at this locus. However, for mammalian ANP32B in birds, the synteny of the surrounding genes suggests that the gene was lost through a chromosomal rearrangement (e.g. an inversion) as the surrounding genes in birds are very different.

In humans, there is an intronless gene named ANP32C, which is unrelated to *Xenopus* ANP32C and Avian ANP32Bs, but is closely related to ANP32A. To avoid confusion, we no longer refer to a ANP32C group but an Avian ANP32B clade and make clear that ANP32C in humans is unrelated to avian ANP32Bs.

Figure 1---figure supplement 2, the Results (first paragraph) and the Discussion (subsection "Viral replication is abrogated in chicken cells lacking ANP32A") have been updated.

To clarify for this reviewer, we now included a schematic of ANP32 nomenclature in [Author response image 1](#respfig1){ref-type="fig"}.

![](elife-45066-resp-fig1){#respfig1}

> 2\) The way the manuscript is written and the data presented are a bit misleading. At the end, the story is that ANP32A, ANP32B and ANP32C are paralogues. Only ANP32A and ANP32B support influenza polymerase replication, with some species-specificity depending on polymerase polymorphisms. ANP32B is not found in avian, and the so called avian ANP32B is in reality ANP32C, and therefore, avian species only have ANP32A to support influenza polymerase activity, as they lack ANP32B. The authors should re-write the Abstract and some of the portions of the manuscript to make this point clear.

The orthology of ANP32 proteins is clarified from point 1. To further clarify, the Abstract has been reworded and the focus is on the 129I residue as the key difference that occurs only in birds and not other members of the clade.

> 3\) Although is clear the deletion or alteration of chicken ANP32A make chicken cells resistant to optimal replication with influenza virus, the authors cannot exclude that if mutations are introduced in chicken that abrogate the ability of ANP32A to promote virus replication, this result in a selective pressure that select for mutant influenza viruses able to use avian ANP32B or mutated avian ANP32A. This should be discussed.

We agree with the reviewers deductions. In future we plan to examine the evolution of virus in cells lacking or with gene edited ANP32A.

We have acknowledged this possibility in the Discussion paragraph three.

> 4\) The authors conclude that PGC aKO are \"effectively resistant\" to influenza virus replication. Yet, Figure 7 shows clear low-level titres that persist throughout the infection and these are noted in the Discussion (paragraph three). A more rigorous assessment is needed to know if these cells support viral replication, both in low MOI multi-cycle and high MOI single-cycle infections. While this could appear to be a semantic distinction, it is critically important for their proposed use of aKO as a bio-control. Any level of viral replication in aKO cells raises the possibility that the virus will adapt, possibly by acquiring the ability to utilise ANP32B. Do viruses recovered at 48hr contain any novel mutations, especially in 7a or 7c-d where titres persist or even increase at later times?

We agree with the authors observations and acknowledge that to describe the aKO PGCs as 'resistant' is misleading. We have altered this to 'resilient' in the manuscript.

We have repeated the virology in the WT and aKO PGC fibroblast cells in order to robustly test their resilience to infection. Previously we did not pH wash cells to remove any virus present in the inoculum for fear of damaging the PGC fibroblasts. Since then we have found they tolerate it well and have disregarded previous virus growth curves as we could not be confident if we were measuring residual virus from the inoculum or true virus amplification. This has been updated in the Materials and methods.

We infected WT and aKO PGC fibroblasts with either PR8 reassortant H5N1 or H7N9 virus at an MOI of 0.0001 or 1.0. We observed no or very limited replication in the aKO cells at the lower MOI and were unable to sequence from this material at the 48 hour time point. However, we observed attenuated replication in aKO cells at the higher MOI.

We sequenced the PB2 gene from the H5N1 and Anhui virus 24hr time point in the high MOI conditions and found the PB2 sequence of viruses from aKO cells to be identical to those from WT cells and the virus input.

It remains unclear how the virus may replicate in the absence of ANP32A at higher MOIs when polymerase activity in the minigenome assay is abrogated and this raises interesting questions to pursue in future experiments.

Changes to the manuscript include the Results, Materials and methods, Discussion and a new version of Figure 7.

> 5\) The authors propose using aKO in chickens as a means to control influenza virus replication. While a potentially interesting approach, the current data limit confidence in this conclusion. Influenza virus rapidly adapts to diverse host environments, with as little as a single amino acid change in the polymerase conveying new functionality in using different ANP32 proteins. It would seem likely that adaptive variants would arise under these conditions. Moreover, knock-out analysis in mice shows that ANP32A plays an important role in embryogenesis, and that this is more pronounced in the absence of ANP32B (Reilly et al., 2011). Will this also occur in chickens, which naturally lack a true ANP32B paralog and where the newly-named ANP32C is nonfunctional in at least its ability to support IAV polymerases? A more tempered and nuanced discussion of the potential of aKOs is warranted.

We understand the reviewer's concern that we are over-stating the impact of our research. We only state here that our data suggest this as a possible and very novel approach. We believe that the data here warrant the generation of ANP32A gene-edited chickens to test this possibility as a next step and we have recently obtained funding to this end. Part of this project will include the examination of virus evolution in conditions where ANP32A is lacking or altered.

We have better represented the limitations of our findings in the Discussion to acknowledge the possible detrimental effect on host of ANP32A modification and discuss the need to examine virus evolution in the future.
